CPT CODE J3301 – Kenalog-40 Injection Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is a synthetic glucocorticoid corticosteroid with anti-inflammatory action.
At the time of manufacture, the air in the container is replaced by nitrogen. KENALOG-10 INJECTION is triamcinolone acetonide, a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intradermal, intra-articular, and intra-bursal injection and for injection into tendon sheaths.
Epicondylitis may be treated by infiltrating the preparation into the area of greatest tenderness. Kenalog ® -40 Injection (triamcinolone acetonide injectable suspension, USP) is supplied in vials providing 40 mg triamcinolone acetonide per mL. Store at controlled room temperature, 20°–25°C (68°–77°F), avoid freezing and protect from light.
Adequate studies to demonstrate the safety of Kenalog Injection use by intraturbinal, subconjunctival, sub-Tenons, retrobulbar, and intraocular (intravitreal) injections have not been performed.
CPT CODE J3301 – Kenalog-40 Injection billing Guide – warnings, side effects.
Triamcinolone Acetonide Injectable Suspension, for Suprachoroidal use (Xipere™) HCPCS Code J3490: Billing Guidelines Effective with date of service Jan. 27, 2022, the Medicaid and NC Health Choice programs cover triamcinolone acetonide injectable suspension.
The CPT code J3301, Kenalog injection is a good example of an NOC code that must be used. Read the user manual for instructions for submitting NDC numbers. You need to change your insurance layout and enter the NDC number using the format specified in the user manual. To report the Kenalog, use the HCPCS code J3301.
HCPCS code J3301 for Injection, triamcinolone acetonide, not otherwise specified, 10 mg as maintained by CMS falls under Drugs, Administered by Injection .
Triamcinolone (Kenalog) is a first-choice injectable medication used to treat gout attacks. It's also used to treat many other conditions, including allergies, skin conditions, multiple sclerosis, and arthritis.
HCPCS code J1030 is defined as “Injection, methylprednisolone acetate, 40 mg.”
KENALOG 40MG/ML 10ML VL EACH (00003-0293-28)mLmgunits1.04041.56062.08082.5100102 more rows•Jan 16, 2018
Report J3301 (4 units). The description for J3301 is for 10 mg, so 4 units = 40 mg.
CPT® code 96372: Injection of drug or substance under skin or into muscle.
Long term (current) use of systemic steroids The 2022 edition of ICD-10-CM Z79. 52 became effective on October 1, 2021. This is the American ICD-10-CM version of Z79.
It is available in brand and generic forms. It is not covered by most Medicare and insurance plans, but manufacturer and pharmacy coupons can help offset the cost.
The intra-articular or soft tissue administration of Kenalog-40 Injection is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis.
Kenalog-40 Injection has an extended duration of effect which may be sustained over a period of several weeks. Studies indicate that following a single intramuscular dose of 60 mg to 100 mg of triamcinolone acetonide, ...
Intramuscular. Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in ...
General. Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants.
Kenalog-40 Injection is contraindicated in patients who are hypersensitive to any components of this product (see WARNINGS: General ).
Cases of serious anaphylaxis, including death, have been reported in individuals receiving triamcinolone acetonide injection, regardless of the route of administration. Because Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is a suspension, it should not be administered intravenously.
Kenalog#N#®-40 Injection (triamcinolone#N#acetonide injectable suspension, USP) is a synthetic glucocorticoid corticosteroid#N#with anti-inflammatory action. THIS FORMULATION IS SUITABLE FOR INTRAMUSCULAR#N#AND INTRA-ARTICULAR USE ONLY. THIS FORMULATION IS NOT FOR INTRADERMAL INJECTION.#N#Each mL of the sterile aqueous suspension provides 40 mg triamcinolone#N#acetonide, with 0.65% sodium chloride for isotonicity, 0.99% (w/v) benzyl alcohol#N#as a preservative, 0.75% carboxymethylcellulose sodium, and 0.04% polysorbate#N#80. Sodium hydroxide or hydrochloric acid may be present to adjust pH to 5.0 to 7.5.#N#At the time of manufacture, the air in the container is replaced by nitrogen.The chemical name for triamcinolone acetonide is 9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione#N#cyclic 16,17-acetal with acetone. Its structural formula is:Triamcinolone acetonide occurs as a white to cream-colored, crystalline#N#powder having not more than a slight odor and is practically insoluble in#N#water and very soluble in alcohol.
as a preservative, 0.75% carboxymethylcellulose sodium, and 0.04% polysorbate. 80. Sodium hydroxide or hydrochloric acid may be present to adjust pH to 5.0 to 7.5.
Dosage Form: Injection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Kenalog-40 Injection is a long-acting preparation, and is. not suitable for use in acute stress situations.
The intra-articular or soft tissue administration of#N#Kenalog-40 Injection is indicated as adjunctive therapy for short-term administration (to tide#N#the patient over an acute episode or exacerbation) in acute gouty arthritis,#N#acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis,#N#rheumatoid arthritis, synovitis, or osteoarthritis.
Exposure to excessive amounts of benzyl alcohol has been associated. with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants, associated.
insufficiency (hydrocortisone or corti sone is the drug of choice ; synthetic. analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative.
The Kenalog strength that is usually used for intralesional injections is 10 mg/ml. Since 1ml is 1cc if they are using 0.2cc that is less than 1 ml so I would code that as 1 unit (can't code less than 1) For our dermatologists it is extremely rare for them to use over 1 cc of kenalog for intradermal lesional injections without needing the 11901 code. If you coded for 20 units (cc's) that would be a red flag to me, I would definitely look into what strength kenalog they are using and how they are using it. Intralesional injections are small amounts injected in various lesions. If one of my doctor's marks 4 units for J3301 then I know it is more likely that they are doing an IM injection of kenalog for an allergic reaction which is a different code altogether.
in mg/ml... you can convert mg/ml to mg/cc as 1 ml = 1 cc. If your medication is at a concentration of 10 mg/ml, then you have 10 mg in 1 cc. you cannot directly convert mg to cc. you need more information from the drug.
J3301 is 10mg, so convert that to cc's. Dr. uses .2cc and there are 1000mg in 1cc, is coding 20 units correct? J.
The NDC Code 0003-0293-28 is assigned to a package of 1 vial, multi-dose in 1 carton > 10 ml in 1 vial, multi-dose of Kenalog-40, a human prescription drug labeled by E.r. Squibb & Sons, L.l.c.. The product's dosage form is injection, suspension and is administered via intra-articular; intramuscular form.
The National Average Drug Acquisition Cost (NADAC) is the average drug invoice price paid by retail community pharmacies to wholesalers. The Centers for Medicare and Medicaid Services (CMS) compile the NADAC data based on random monthly surveys on more than 60,000 pharmacies from all 50 states and the District of Columbia.
This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.
The following packages are also available for Kenalog-40 with product NDC 0003-0293.
The intra-articular or soft tissue administration of Kenalog-40 Injection is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis.
Exposure to excessive amounts of ben zyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources (see PRECAUTIONS: Pediatric Use).
This product contains benzyl alcohol as a preservative. Benzyl alcohol , a component of this product, has been associated with serious adverse events and death, particularly in pediatric patients. The “gasping syndrome” (characterized by central nervous system depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages >99 mg/kg/day in neonates and low-birth-weight neonates. Additional symptoms may include gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Although normal therapeutic doses of this product deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the “gasping syndrome,” the minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birth-weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources.